Stocktoria
REPLIGEN CORP RGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1986-04-29
REPLIGEN CORP statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 7.5% | -5.5% | 7.5% | 28.0% | 24.9% |
| Net margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% |
| FCF margin | 12.7% | 23.6% | 12.3% | 10.9% | 7.7% |
| Return on assets | 1.7% | -0.9% | 1.3% | 7.4% | 5.4% |
| Return on equity | 2.3% | -1.3% | 1.8% | 9.7% | 7.3% |
| Debt / equity | 0.26× | 0.27× | — | — | — |
| Current ratio | 8.37 | 8.41 | 6.74 | 2.47 | 2.48 |
| Revenue growth | 16.4% | 0.3% | -21.1% | 19.5% | 83.1% |
Source: SEC EDGAR filings · CIK 0000730272 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.